Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc., traded under the symbol VNDA on Nasdaq, is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies. Vanda's primary focus is on addressing high unmet medical needs to improve the lives of patients. The company's commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, and Fanapt for schizophrenia. Recently added to its portfolio is PONVORY, a treatment for multiple sclerosis.
Other promising products in Vanda's pipeline include VHX-896, ASO Molecules, VQW-765, Tradipitant (in clinical studies for gastroparesis and motion sickness), and VTR-297. Vanda's robust R&D efforts are highlighted by substantial advancements, such as the initiation of clinical programs in conditions like depression, psoriasis, ulcerative colitis, and pediatric insomnia.
In recent financial news, Vanda reported a net loss of $4.1 million for Q1 2024, a shift from a net income of $3.3 million in Q1 2023. Despite this, the company maintains a strong cash position and expects significant growth from upcoming milestones, including the launch of Fanapt in acute bipolar I disorder and PONVORY in multiple sclerosis.
Recently, Vanda made headlines with the FDA approval of tradipitant for preventing vomiting induced by motion sickness, and the commencement of a comprehensive marketing program for PONVORY following its acquisition from a Johnson & Johnson company. Additional corporate activities involve evaluating unsolicited acquisition proposals, indicating a strategic interest in Vanda’s innovative portfolio.
For more detailed information, investors can visit www.vandapharma.com and follow Vanda on social media platforms.
Vanda Pharmaceuticals confirmed receiving an unsolicited, non-binding indication of interest from Cycle Group Holdings to acquire the company for $8.00 per share in cash.
The Vanda Board of Directors will review the offer with their financial and legal advisors to determine the best course of action for the company and its shareholders.
No shareholder action is required at this time, and Vanda does not intend to comment further until the review is complete.
Cycle Pharmaceuticals has proposed an all-cash acquisition of Vanda Pharmaceuticals at $8.00 per share, representing a 98% premium over Vanda's closing price on April 16, 2024. This proposal exceeds the latest offer from Future Pak and provides a compelling value for Vanda shareholders. Cycle assures full financing and no contingency on this offer, valuing the transaction at $466 million. The proposal aims to offer immediate and certain cash value, benefiting both shareholders and patients due to Cycle's strong U.S. presence and proven commercial strategy. Cycle is ready to negotiate and finalize the agreement swiftly.
Vanda Pharmaceuticals will participate in the Jefferies 2024 Global Healthcare Conference in New York City on June 6, 2024. The company will deliver a corporate presentation at 2:00 p.m. ET, accessible live on Vanda's corporate website. Investors can register and view the presentation by clicking on the Investors tab and following the link under Recent Events. A recording of the presentation will be available on the website for 30 days post-conference.
Vanda Pharmaceuticals announced the completion of the transfer of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod) from a Johnson & Johnson Company on May 30, 2024. This milestone enables Vanda to fully commercialize PONVORY® in the U.S. and commence clinical development programs. PONVORY® is approved by the FDA and Health Canada for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (RMS). Vanda acquired U.S. and Canadian rights to PONVORY® on December 7, 2023. In preparation for a Q3 2024 commercial launch, Vanda is creating a specialty sales force, a prescriber awareness program, and a comprehensive marketing strategy.
Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency, genetic variants linked to dim light melatonin onset in delayed sleep-wake phase disorder (DSWPD) patients, and genetic variants associated with total sleep time (TST) and latency to persistent sleep (LPS) in insomnia patients based on whole genome sequencing.
On May 24, 2024, Vanda Pharmaceuticals' Board of Directors announced its unanimous decision to reject Future Pak, 's revised unsolicited takeover proposal. The offer included a cash price of $7.25 to $7.75 per share plus Contingent Value Rights (CVRs). The Board, advised by independent financial and legal experts, concluded that the proposal undervalues Vanda, poses significant risks, and is not in shareholders' best interests. Key considerations included Vanda's clinical development pipeline, robust revenue, strong cash position, and the speculative nature of the CVRs. Vanda remains confident in its potential for long-term growth and value creation.
Vanda Pharmaceuticals announced positive results from the second Phase III study of tradipitant for motion sickness. Conducted in real-world conditions, the study involved 316 participants on boat trips across the U.S. coast between September 2023 and April 2024. Tradipitant significantly reduced vomiting, with 10.4% and 18.3% of participants experiencing vomiting on 170 mg and 85 mg doses, respectively, compared to 37.7% on placebo. Additionally, 13.3% of participants reported severe nausea and vomiting on tradipitant versus 33% on placebo. Vanda plans to submit a New Drug Application (NDA) for tradipitant in Q4 2024.
Vanda Pharmaceuticals reported their first quarter 2024 financial results with revenues of $47.5 million, a 5% increase from the previous quarter. The company achieved various milestones, including FDA approval for Fanapt® in bipolar I disorder, with commercial launch expected in Q3 2024. Additionally, they anticipate submitting the NDA for Milsaperidone in schizophrenia and bipolar disorder in early 2025. Vanda also expects to launch PONVORY® for multiple sclerosis in Q3 2024 and has ongoing clinical trials for Tradipitant for various conditions. Financially, total net product sales decreased by 24% compared to the first quarter of 2023. Net loss was $4.1 million, and cash reserves increased to $394.1 million. Despite challenges, Vanda remains optimistic about future growth.
Vanda Pharmaceuticals has received a revised unsolicited takeover proposal from Future Pak offering $7.25 to $7.75 per share in cash plus Contingent Value Rights. Vanda's Board of Directors will review the proposal to determine the best course of action. Shareholders do not need to take any action at this time.
Future Pak has increased its offer for Vanda Pharmaceuticals, including Contingent Value Rights (CVRs) along with $7.25 to $7.75 per share in cash. The increased offer could provide up to $260 million in potential value, translating to $11.62 to $12.12 per share, a 187% to 199% premium to Vanda's unaffected share price. Despite Vanda's actions to limit shareholder influence, Future Pak remains committed to the transaction.
FAQ
What is the current stock price of Vanda Pharma (VNDA)?
What is the market cap of Vanda Pharma (VNDA)?
What does Vanda Pharmaceuticals Inc. specialize in?
Which products are currently in Vanda's commercial portfolio?
What is HETLIOZ used for?
What is the latest financial update from Vanda?
What significant milestones does Vanda expect in the near future?
What recent product approval has Vanda received?
What is PONVORY, and what does it treat?
What recent corporate actions has Vanda undertaken?
How can investors access Vanda’s financial results conference call?
Where can I find more information about Vanda Pharmaceuticals?
